| | 
Part, Chapter, Paragraph
1 I, 2. 3 | European Union alone, 500 000 girls and women are affected
2 I, 2. 7 | Hammarby Sjostad zone, 10,000 flats for 25,000 inhabitants,
3 I, 2. 7 | zone, 10,000 flats for 25,000 inhabitants, is an example
4 I, 2. 7 | created, to be inhabited by 80,000 people. It will be named
5 I, 3. 2 | and migration rate (per 1,000 population), 2005~ ~The
6 II, 5. 2. 1 | accounting for over 741,000 deaths every year (one in
7 II, 5. 2. 1 | the EU accounting for 508,000 deaths each year: around
8 II, 5. 2. 3 | accounting for over 741.000 deaths every year: one in
9 II, 5. 2. 3 | from 42.7 deaths per 100.000 in France to 327.0 deaths
10 II, 5. 2. 3 | to 327.0 deaths per 100.000 in Latvia, being there almost
11 II, 5. 2. 3 | in men 72 deaths per 100.000 in France and 555 in Latvia;
12 II, 5. 2. 3 | Latvia; in women 16 per 100.000 in France and 167 in Latvia).~ ~
13 II, 5. 2. 3 | mortality rates per 100.000.~ ~Mortality trends for
14 II, 5. 2. 3 | from 300 to 186 per 100.000), 45% in Central Eastern
15 II, 5. 2. 3 | from 440 to 242 per 100.000), 27% in Eastern Europe
16 II, 5. 2. 3 | from 450 to 326 per 100.000), 37% in Central Europe
17 II, 5. 2. 3 | from 225 to 142 per 100.000), 34% in Southern Europe
18 II, 5. 2. 3 | from 139 to 91 per 100.000) and 27% in Baltic7 countries (
19 II, 5. 2. 3 | from 696 to 505 per 100.000). Similar results can be
20 II, 5. 2. 3 | countries (from 73 to 44 per 100.000), 51% in Central Eastern
21 II, 5. 2. 3 | from 157 to 77 per 100.000), 23% in Eastern Europe
22 II, 5. 2. 3 | from 169 to 130 per 100.000), 41% in Northern Europe (
23 II, 5. 2. 3 | from 102 to 61 per 100.000), 36% in Baltic Europe countries (
24 II, 5. 2. 3 | from 231 to 148 per 100.000) and 41% in Southern Europe
25 II, 5. 2. 3 | countries (from 40 to 23 per 100.000).~ ~Figure 5.2.1. Age-standardized
26 II, 5. 2. 3 | mortality rates per 100.000. Trends for ischemic heart
27 II, 5. 2. 3 | mortality rates per 100.000. Trends for ischemic heart
28 II, 5. 2. 3 | hospital discharge rates (x100.000) from all CVD, IHD,AMI,
29 II, 5. 2. 3 | recurrent events) per 100.000 during 10-year registration
30 II, 5. 2. 3 | accounting for over 508.000 deaths each year. Around
31 II, 5. 2. 3 | mortality rates per 100.000 men and women aged 35-74
32 II, 5. 2. 3 | varies from 60 deaths per 100.000 in France to 399 deaths
33 II, 5. 2. 3 | France to 399 deaths per 100.000 in Romania, being there
34 II, 5. 2. 3 | varies from 36 deaths per 100.000 in France to 297 deaths
35 II, 5. 2. 3 | from 133 to 49 per 100.000), 40% in Southern Europe
36 II, 5. 2. 3 | from 136 to 82 per 100.000), 21% in Northern countries (
37 II, 5. 2. 3 | from 110 to 87 per 100.000), 34% in Central Eastern
38 II, 5. 2. 3 | from 273 to 180 per 100.000) and 6% in Baltic Europe
39 II, 5. 2. 3 | from 298 to 279 per 100.000). Mortality increased by
40 II, 5. 2. 3 | from 324 to 357 per 100.000). In 2003, mortality rates
41 II, 5. 2. 3 | mortality rates per 100.000 Cerebrovascular disease (
42 II, 5. 2. 3 | Europe (from 89 to 54 per 100.000), 46% in Southern Europe
43 II, 5. 2. 3 | countries (from 99 to 54 per 100.000), 21% in Northern countries (
44 II, 5. 2. 3 | countries (from 87 to 68 per 100.000), 13% in Baltic Europe countries (
45 II, 5. 2. 3 | from 218 to 189 per 100.000) and 37% in Central Eastern
46 II, 5. 2. 3 | from 193 to 121 per 100.000). Mortality rates increased
47 II, 5. 2. 3 | from 203 to 246 per 100.000). In 2003, mortality rates
48 II, 5. 2. 3 | mortality rates per 100.000 Cerebrovascular disease (
49 II, 5. 2. 3 | fatal and non fatal) per 100.000 mean of the last 3 years
50 II, 5. 2. 6 | prospective studies with 55,000 vascular deaths. Lancet
51 II, 5. 3. 1 | new cancer cases per 100,000 population at risk;~ ~-
52 II, 5. 3. 1 | deaths for cancer per 100,000 population at risk;~ ~-
53 II, 5. 3. 5 | performance. In 2006, 3,200,000 new cases and 1,700,000
54 II, 5. 3. 5 | 000 new cases and 1,700,000 deaths were estimated for
55 II, 5. 3. 5 | men (599 new cases per 100,000) and in Denmark for women (
56 II, 5. 3. 5 | women (414 new cases per 100,000). Maximum mortality rates (
57 II, 5. 3. 5 | men (364 deaths per 100,000) and in Denmark for women (
58 II, 5. 3. 5 | women (196 deaths per 100,000). The highest incidence
59 II, 5. 3. 5 | men (482 new cases per 100,000, Figure 5.3.2a) and in Northern
60 II, 5. 3. 5 | women (351 new cases per 100,000, Figure 5.3.2b), while the
61 II, 5. 3. 5 | men (287 deaths per 100,000, Figure 5.3.4a) and again
62 II, 5. 3. 5 | women (155 deaths per 100,000, Figure 5.3.4b).~Figures
63 II, 5. 3. 5 | In 2006 Europe saw, 160,000 new cases and 118,000 deaths
64 II, 5. 3. 5 | 160,000 new cases and 118,000 deaths estimated for stomach
65 II, 5. 3. 5 | men (37 new cases per 100,000) and in Lithuania for women (
66 II, 5. 3. 5 | women (18 new cases per 100,000); while maximum levels of
67 II, 5. 3. 5 | for men (29 deaths per 100,000) and in Estonia for women (
68 II, 5. 3. 5 | women (12 deaths per 100,000). Incidence and mortality
69 II, 5. 3. 5 | ICD-9 153, 154)~In 2006, 413,000 new cases and 207,000 deaths
70 II, 5. 3. 5 | 413,000 new cases and 207,000 deaths were estimated for
71 II, 5. 3. 5 | men (106 new cases per 100,000) and Switzerland for women (
72 II, 5. 3. 5 | women (56 new cases per 100,000). Finland had lower male
73 II, 5. 3. 5 | and 41 new cases per 100,000 in women). Figures 5.3.11
74 II, 5. 3. 5 | over 40 deaths per 100,000) and for women (over 24
75 II, 5. 3. 5 | over 24 deaths per 100,000).~Colorectal cancer incidence
76 II, 5. 3. 5 | in Europe there were 386,000 new cases and 335,000 estimated
77 II, 5. 3. 5 | 386,000 new cases and 335,000 estimated deaths (Ferlay
78 II, 5. 3. 5 | cases and 110 deaths per 100,000) against Sweden with minimum
79 II, 5. 3. 5 | cases and 29 deaths per 100,000). Sweden had a lower male
80 II, 5. 3. 5 | vs 41 new cases per 100,000). Eastern Europe had maximum
81 II, 5. 3. 5 | cases and 85 deaths per 100,000). While Northern Europe
82 II, 5. 3. 5 | cases and 27 deaths per 100,000 in 2006).~Most European
83 II, 5. 3. 5 | women with an estimated 430,000 new cases and 132,000 deaths
84 II, 5. 3. 5 | 430,000 new cases and 132,000 deaths in 2006 for the entire
85 II, 5. 3. 5 | Belgium (138 new cases per 100,000). Breast cancer incidence
86 II, 5. 3. 5 | Iceland) to 34 deaths per 100,000 (in Denmark). Mortality
87 II, 5. 3. 5 | estimates were about 60,000 new cases and 30,000 deaths
88 II, 5. 3. 5 | 60,000 new cases and 30,000 deaths in 2002 for the entire
89 II, 5. 3. 5 | ICD-9 185)~In 2006, 346,000 new cases and 87,000 deaths
90 II, 5. 3. 5 | 346,000 new cases and 87,000 deaths were estimated for
91 II, 5. 4. 2 | Type 1 diabetes by age/100,000 population 0–14 years~12~
92 II, 5. 4. 2 | patients with diabetes/1,000,000 general population~11~
93 II, 5. 4. 2 | patients with diabetes/1,000,000 general population~11~HIS/
94 II, 5. 4. 2 | patients with diabetes /1,000,000 general population~11~
95 II, 5. 4. 2 | patients with diabetes /1,000,000 general population~11~HIS/
96 II, 5. 4. 2 | death diabetes mellitus/100,000 general population~12~National
97 II, 5. 4. 2 | population from all causes /100,000 general population, adjusted
98 II, 5. 4. 2 | children in one year per 100.000 children.~Prevalence of
99 II, 5. 4. 2 | replacement therapy) per 100,000 individuals in the diabetic
100 II, 5. 4. 2 | transplantation per 100.000 diabetic population is defined
101 II, 5. 4. 2 | transplantation per 100,000 individuals in the diabetic
102 II, 5. 4. 2 | death diabetes mellitus/100,000 general population. Despite
103 II, 5. 4. 2 | in diabetic patients /100,000 general population~9~Annual
104 II, 5. 4. 2 | in diabetic patients /100,000 general population~10~Annual
105 II, 5. 4. 2 | in diabetic patients/100,000 general population~10~ ~
106 II, 5. 4. 2 | amputations (above ankle) per 100,000 individuals in the diabetic
107 II, 5. 4. 2 | ischemic and bleeding) per 100,000 individuals in the diabetic
108 II, 5. 4. 2 | myocardial infarction per 100,000 individuals in the diabetic
109 II, 5. 4. 3 | Finland) cases per 100,000 per year. The median value
110 II, 5. 4. 3 | to 149 (Scotland) per 100,000, with a median of 79 (Denmark).
111 II, 5. 4. 3 | transplantation per 100.000 diabetic population. Across
112 II, 5. 4. 3 | median of 304 every 100,000 diabetics, corresponding
113 II, 5. 4. 3 | and 199 (Portugal) per 100,000 in 10 countries delivering
114 II, 5. 4. 3 | The median value is 31/100,000, corresponding to France.
115 II, 5. 4. 3 | 2007 a total of over 300,000 deaths are attributable
116 II, 5. 4. 3 | to 574 (Spain) per 100,000 diabetes patients, with
117 II, 5. 4. 3 | a median of 669 per 100,000. There is a clear influence
118 II, 5. 4. 4 | town of Europe with 100 000 inhabitants would loose
119 II, 5. 5.Int | varies between 3 and 6 per 1.000 inhabitants. Data, though
120 II, 5. 5. 1 | Across the EU, about 59 000 citizens, 45 000 men and
121 II, 5. 5. 1 | about 59 000 citizens, 45 000 men and 14 000 women committed
122 II, 5. 5. 1 | citizens, 45 000 men and 14 000 women committed suicide
123 II, 5. 5. 1 | road accidents of about 50 000 deaths (Eurostat). The EU
124 II, 5. 5. 1 | disorders as total per 100 000 population for newly diagnosed
125 II, 5. 5. 1 | self-inflicted injury per 100 000 population. Age standardisation
126 II, 5. 5. 1 | intentional self-harm per 100 000 whole population (standardized
127 II, 5. 5. 1 | inflicted accidents per 100 000 people by country and gender
128 II, 5. 5. 1 | inflicted accidents (per 100 000 people) by gender in Europe~ ~
129 II, 5. 5. 1 | inflicted accidents (per 100 000) in Europe.~ ~The changes
130 II, 5. 5. 1 | global level, 70 per 100 000 and Lithuanian women have
131 II, 5. 5. 1 | the world with 14 per 100 000 (WHO statistics).~ ~
132 II, 5. 5. 3 | bulimia affects 30 per 100.000 females, whereby the incidence
133 II, 5. 5. 3 | incidence rate of 81,1 per 100.000 (Hoek and van Hoeken, 2003).~
134 II, 5. 5. 3 | of Eating Disorder 00:0 000-000 2008-DOI 10.1002/eat.~
135 II, 5. 5. 3 | Eating Disorder 00:0 000-000 2008-DOI 10.1002/eat.~Misra
136 II, 5. 5. 3 | lifetime is about seven per 1 000 people. The latest available
137 II, 5. 5. 3 | prevalence of 4.6 per 1 000, 3.3 for period prevalence,
138 II, 5. 5. 3 | between 16 and 42 per 100 000 population experience a
139 II, 5. 5. 3 | F20-death rates per 100 000 inhabitants would allow
140 II, 5. 5. 3 | Considering in-patients per 1,000 populations (see Figure
141 II, 5. 5. 3 | psychologists from 0.1 to 96 per 100 000 population (WHO, 2005c).
142 II, 5. 5. 3 | eight-year-olds (65.88 per 10,000) were identified as having
143 II, 5. 5. 3 | finding of 6.6 and 6.7 per 1,000 eight-year-olds translates
144 II, 5. 5. 3 | Disorders (ASD) from 4 per 10,000 to 66 per 10000 children
145 II, 5. 5. 3 | ranges from 44 to 73 per 100,000, while the incidence of
146 II, 5. 5. 3 | ranges from 24 to 57 per 100,000 (Forsgren et al, 2005; Olafsson
147 II, 5. 5. 3 | 4.2. Incidence (per 100,000) of epilepsy in Europe,
148 II, 5. 5. 3 | incidence 23.5 per 100,000 per year). Undetermined
149 II, 5. 5. 3 | occurred in 15% (8.7 per 100,000 per year), cryptogenic localization-related
150 II, 5. 5. 3 | epilepsy in 16% (8.8 per 100,000 per year), symptomatic localization-related
151 II, 5. 5. 3 | epilepsy in 15% (8.4 per 100,000 per year), and idiopathic
152 II, 5. 5. 3 | epilepsy in 6% (3.4 per 100,000 per year). In Bordeaux,
153 II, 5. 5. 3 | The rate was 15.3 per 100,000 for localization-related
154 II, 5. 5. 3 | symptomatic 13.6), 6.7 per 100,000 for generalized epilepsies (
155 II, 5. 5. 3 | symptomatic 1.1) and 1.9 per 100,000 for undetermined epilepsies (
156 II, 5. 5. 3 | ranges from 3.2 to 7.8 per 1,000 (Table 5.5.3.4.3). The prevalence
157 II, 5. 5. 3 | Prevalence ratio (per 1,000)~Reference(s), year~ ~Denmark ~
158 II, 5. 5. 3 | epilepsies was 1.2 per 1,000, while that of cryptogenic
159 II, 5. 5. 3 | epilepsies was 1.0 per 1,000. In another study of childhood
160 II, 5. 5. 3 | syndromic category (1.5 per 1,000) followed by generalized
161 II, 5. 5. 3 | generalized epilepsies (1.3 per 1,000) and undetermined epilepsies (
162 II, 5. 5. 3 | undetermined epilepsies (0.6 per 1,000). Localization-related epilepsies
163 II, 5. 5. 3 | ranges from 1 to 8 per 100,000 population per year, but
164 II, 5. 5. 3 | mortality rates at 1-2 per 100,000 (Massey et al, 1985).~In
165 II, 5. 5. 3 | mortality rate of 6.23 per 1,000 person-years was reported (
166 II, 5. 5. 3 | SUDEP ranges from 1 per 1,000 in prevalence studies (O’
167 II, 5. 5. 3 | Sander, 1997) to 3.5 per 1,000 in incidence studies (Nashef
168 II, 5. 5. 3 | SUDEP was 2.5 vs. 6.3 per 1,000 (Nilsson et al, 2003). There
169 II, 5. 5. 3 | cohort study of more than 9,000 patients once hospitalized
170 II, 5. 5. 3 | population-based studies (ie, 50 000 pop. and over, registry-based
171 II, 5. 5. 3 | 5.2. Prevalence (per 100 000) of Multiple Sclerosis in
172 II, 5. 5. 3 | 5.3. Prevalence (per 100 000) of Multiple Sclerosis in
173 II, 5. 5. 3 | 5.4. Incidence (per 100 000/year) of Multiple Sclerosis
174 II, 5. 5. 3 | significantly from 3 to 6 per 100 000 per year in the western
175 II, 5. 5. 3 | in France is 65 per 100 000 (Vukusic et al, 2007), and
176 II, 5. 5. 3 | Prevalence of 39 and 21 per 100 000 has been reported for Bulgaria
177 II, 5. 5. 3 | approx. 20 to 190 per 100 000. Mean rates are higher in
178 II, 5. 5. 3 | between 11 and 282 per 100 000 in women and between 10
179 II, 5. 5. 3 | between 10 and 123 per 100 000 in men, with female:male
180 II, 5. 5. 3 | estimated to be 4 per 100 000, with peaks registered registered
181 II, 5. 5. 3 | from 0.6 to 1.0 per 100 000 as reported by WHO for 2002 (
182 II, 5. 5. 3 | rates up to 3.6 per 100 000 are reported in the scientific
183 II, 5. 5. 3 | 5.7. Mortality (per 100 000) of MS patients in selected
184 II, 5. 5. 3 | for MS in Europe is 307 000 years and varies according
185 II, 5. 5. 3 | mortality strata, being 157 000 in the very-low-child/very-low-adult
186 II, 5. 5. 3 | very-low-adult stratum, 63 000 in the low-child/low-adult
187 II, 5. 5. 3 | low-child/low-adult and 87 000 in the low-child/high-adult
188 II, 5. 5. 3 | in Europe ranges from €10 000 to €54 000, with a mean
189 II, 5. 5. 3 | ranges from €10 000 to €54 000, with a mean of €31 000.
190 II, 5. 5. 3 | 000, with a mean of €31 000. Direct costs, excluding
191 II, 5. 5. 3 | prevalence (MSA:1.86 to 4.9/100.000, PSP: 2.5 to 7.5/100.000;
192 II, 5. 5. 3 | 000, PSP: 2.5 to 7.5/100.000; CGD: 4.0/100.000, respectively (
193 II, 5. 5. 3 | 5/100.000; CGD: 4.0/100.000, respectively (Nath et al,
194 II, 5. 5. 3 | age groups (>85y; 2205/100.000), however, approximately
195 II, 5. 5. 3 | estimates varied from 5/100,000 to 346/100,000. The latter
196 II, 5. 5. 3 | from 5/100,000 to 346/100,000. The latter estimate is
197 II, 5. 5. 3 | considerably, from 65.6/100,000 in Sardinia (Rosati et al,
198 II, 5. 5. 3 | al, 1980) to 12,500/100,000 for institutionalised patients
199 II, 5. 5. 3 | approximately 120 to 257/100,000 and 11 to 19/100,000 per
200 II, 5. 5. 3 | 100,000 and 11 to 19/100,000 per year, respectively.
201 II, 5. 5. 3 | higher: 1,280 to 1,500/100,000 and 346/100,000, respectively.
202 II, 5. 5. 3 | 500/100,000 and 346/100,000, respectively. The large
203 II, 5. 5. 3 | rates (65.6 to 12,500/100,000) may be the consequence
204 II, 5. 5. 3 | prevalence of 12,500/100,000 was obtained from a study
205 II, 5. 5. 3 | Europe range from 5 per 100,000 to 26 per 100,000, according
206 II, 5. 5. 3 | per 100,000 to 26 per 100,000, according to the identified
207 II, 5. 5. 3 | incidence rate of 326 per 100,000 for people aged 65-84 (Baldereschi
208 II, 5. 5. 3 | from €2,500 (Estonia) – €13,000 (Switzerland) with an average
209 II, 5. 6. 3 | and 140 procedures / 100,000 (Merx et al, 2003). The
210 II, 5. 6. 3 | range from 4–13 per 100,000 for adult males and 13-36
211 II, 5. 6. 3 | males and 13-36 per 100,000 for adult females. Estimates
212 II, 5. 6. 3 | age, with rates of 2/100,000 person-years in women aged
213 II, 5. 6. 3 | under 35,rising to 3032/100,000 person-years in women 85
214 II, 5. 6. 3 | incidences of 9 and 37 per 10 000 men and women respectively,
215 II, 5. 7. 1 | entails a cost excess of $26.000 per case per year in the
216 II, 5. 8. 1 | under-treated.~ ~ ~Approximately 200 000-300 000 people die every
217 II, 5. 8. 1 | Approximately 200 000-300 000 people die every year in
218 II, 5. 8. 3 | geographical areas with nearly 5 000 patients, has estimated
219 II, 5. 8. 3 | from 1.9 to 2.9 per 1 000) in males and by 90% in
220 II, 5. 8. 3 | females (from 1.0 to 2.9 per 1 000) from 2000 to 2025 (Hoogendoorn
221 II, 5. 8. 3 | disease severity, data from 18 000 young adults (20–44 years)
222 II, 5. 8. 3 | symptomatic.~ ~Prevalence (per 1 000 in Dutch population) reported
223 II, 5. 8. 3 | 300 lost work days per 100 000 population are due to this
224 II, 5. 8. 3 | 300 € in Spain and 150, 3 000, 3 900 in Italy, respectively
225 II, 5. 9. 2 | stages including more than 18,000 individuals aged 20 to 44
226 II, 5. 9. 2 | prospective survey of more than 10,000 young adults begun in 1998.~ ~
227 II, 5. 9. 3 | are estimated to be 250,000 per year worldwide. EU mortality
228 II, 5. 9. 3 | Standardized Death Rates (per 100,000 people) in all EU Countries
229 II, 5. 9. 3 | people suggest that: 665.000 people with wheezing are
230 II, 5. 11. 3 | cases of melanoma per 100,000. Many cancer registries
231 II, 5. 11. 3 | skinned population (per 100 000).~ ~ ~There is little information
232 II, 5. 11. 3 | incidence rate of 88 per 100 000 for BCC, of 29 per 100 000
233 II, 5. 11. 3 | 000 for BCC, of 29 per 100 000 for SCC and 14 per 100 000
234 II, 5. 11. 3 | 000 for SCC and 14 per 100 000 for melanoma (de Rijke et
235 II, 5. 11. 3 | that in 2000 there were 132 000 cases of melanoma diagnosed
236 II, 5. 11. 3 | diagnosed world-wide and 37 000 deaths caused by melanoma.
237 II, 5. 11. 3 | that in 2000 there were 35 000 cases of melanoma diagnosed
238 II, 5. 11. 3 | high-resource countries (104 000 cases and 25 000 deaths)
239 II, 5. 11. 3 | countries (104 000 cases and 25 000 deaths) and low- and medium-resource
240 II, 5. 11. 3 | countries (28 500 cases and 12 000 deaths) (Ferlay et al, 2001).
241 II, 5. 12. 1 | rates (around 30-40/100,000 men and 10-16/100,000 women)
242 II, 5. 12. 1 | 100,000 men and 10-16/100,000 women) in Europe were observed
243 II, 5. 12. 1 | lowest ones (below 10/100,000 men and 5/100,000 women)
244 II, 5. 12. 1 | 10/100,000 men and 5/100,000 women) were registered in
245 II, 5. 12. 1 | reaching rates over 58/100,000 men and 22/100,000 women
246 II, 5. 12. 1 | 58/100,000 men and 22/100,000 women in Hungary in 1990 (
247 II, 5. 12. 2 | Age-standardized rates per 100,000 population, at all ages
248 II, 5. 12. 3 | rates from cirrhosis per 100,000 men at all ages and at 35-
249 II, 5. 12. 3 | i.e. Portugal (38.7/100,000), Italy (35.0), France (
250 II, 5. 12. 3 | England and Wales (3.6/100,000), Ireland (3.4), Norway
251 II, 5. 12. 3 | rates between 12 and 15/100,000, and Portugal of around
252 II, 5. 12. 3 | Portugal of around 18/100,000. Similar declines were observed
253 II, 5. 12. 3 | rates were around 10-13/100,000 men in the early 1980s and
254 II, 5. 12. 3 | early 1980s and around 5/100,000 in 2000-02. Consequently,
255 II, 5. 12. 3 | rates remained around 5/100,000 men throughout all the calendar
256 II, 5. 12. 3 | in 1980-82 to 18-20/100,000 in 2000-02, and even smaller
257 II, 5. 12. 3 | in 2000-02 were 31-35/100,000 men. Eight European countries
258 II, 5. 12. 3 | 11.3 in 1980-82 to 15/100,000 in 2000-2002, Finland from
259 II, 5. 12. 3 | rates reaching 172.2/100,000 men in Hungary and 106.1
260 II, 5. 12. 3 | middle-aged men (around 75/100,000).~Mortality rates from cirrhosis
261 II, 5. 12. 3 | in 2000-02 were 22.6/100,000 in Romania, followed by
262 II, 5. 12. 3 | lowest ones, below 2/100,000, were in Greece and Malta.
263 II, 5. 12. 3 | for women were 53.9/100,000 in Hungary and 44.3 in Romania.
264 II, 5. 12. 3 | cirrhosis (around 24-30/100,000).~ ~Table 5.12.2. Age-adjusted (
265 II, 5. 12. 3 | rates from cirrhosis per 100,000 women at all ages and at
266 II, 5. 14. 2 | number and rates (per 100,000 population) of active dentists,
267 II, 5. 14. 2 | clinical providers per 100,000 population.~Denominator:
268 II, 5. 15. 1 | threshold as around 1 in 2,000 (precisely 1 in 2,000 in
269 II, 5. 15. 1 | 2,000 (precisely 1 in 2,000 in Europe).~For the organisation
270 II, 5. 15. 1 | is probably around 1 in 5 000 or 1 in 10 000~( ht ).~From
271 II, 5. 15. 1 | around 1 in 5 000 or 1 in 10 000~( ht ).~From a public health
272 II, 5. 15. 1 | is probably around 1 in 1 000.~ ~Therefore, although it
273 II, 5. 15. 1 | that there are between 5 000 and 8 000 distinct rare diseases,
274 II, 5. 15. 1 | are between 5 000 and 8 000 distinct rare diseases,
275 II, 5. 15. 2 | contains a list of over 5 000 RD and provides textual
276 II, 5. 15. 3 | very low numbers. Of the 5,000 RD listed in Orphanet, only
277 II, 5. 15. 3 | ranging from 5 to 1 in 10 000 and 233 RD have a prevalence
278 II, 5. 15. 3 | ranging between 1 in 10 000 and 1 in 100 000. Another
279 II, 5. 15. 3 | 1 in 10 000 and 1 in 100 000. Another 1 000 RD have probably
280 II, 5. 15. 3 | 1 in 100 000. Another 1 000 RD have probably a prevalence
281 II, 5. 15. 3 | records (HDRs), is 5 per 1 000 inhabitants with a confidence
282 II, 6. 3. 2 | year can be estimated at 3 000 000, and approximately 50
283 II, 6. 3. 2 | can be estimated at 3 000 000, and approximately 50 000
284 II, 6. 3. 2 | 000, and approximately 50 000 deaths occur every year
285 II, 6. 3. 2 | of the infection. Of 87 000 patients staying more than
286 II, 6. 3. 3 | it is estimated that 720 000 people were living with
287 II, 6. 3. 3 | of 2005 and that about 15 000 individuals are becoming
288 II, 6. 3. 3 | Iceland with 552.45 per 100 000, followed by Denmark with
289 II, 6. 3. 3 | Denmark with 441.29 per 100 000. Available data show that
290 II, 6. 3. 3 | up to 200 cases per 100 000 per year in 1995, to below
291 II, 6. 3. 3 | 1995, to below 40 per 100 000 per year in 2004. In the
292 II, 6. 3. 3 | in the UK (33.98 per 100 000), followed by Latvia (30.
293 II, 6. 3. 3 | by Latvia (30.09 per 100 000) and the lowest in Luxembourg (
294 II, 6. 3. 3 | Luxembourg (0.22 per 100 000), followed by Spain and
295 II, 6. 3. 3 | both with 0.42 per 100 000). However, different surveillance
296 II, 6. 3. 3 | under 3.5 to 2.2 per 100 000 per year in 2000, but has
297 II, 6. 3. 3 | then reaching 3.1 per 100 000 per year in 2004, mainly
298 II, 6. 3. 3 | 1990s (over 60 cases per 100 000 per year in 1995), a sharp
299 II, 6. 3. 3 | remained below 10 cases per 100 000 per year, with an overall
300 II, 6. 3. 3 | in Latvia (19.21 per 100 000), Lithuania (8.61 per 100
301 II, 6. 3. 3 | Lithuania (8.61 per 100 000) and Estonia (8.24 per 100
302 II, 6. 3. 3 | and Estonia (8.24 per 100 000), with the 25–44 age group
303 II, 6. 3. 3 | sex partners.~ ~Almost 180 000 cases of Hepatitis B were
304 II, 6. 3. 3 | 6.6 to 2.6 cases per 100 000 per year over the period.
305 II, 6. 3. 3 | by Iceland (11.24 per 100 000), followed by Latvia (7.
306 II, 6. 3. 3 | by Latvia (7.37 per 100 000). Incidence was higher in
307 II, 6. 3. 3 | steadily from 7.0 per 100 000 per year in 2001, to 7.9
308 II, 6. 3. 3 | in 2001, to 7.9 per 100 000 per year in 2004, but this
309 II, 6. 3. 3 | artefact. In 2005, more than 29 000 hepatitis C cases were reported
310 II, 6. 3. 3 | incidence rates per 100 000 per year were reported by
311 II, 6. 3. 4 | remained below 20 per 100 000 per year since 2001 in all
312 II, 6. 3. 4 | 6.A1.1 TB cases per 100,000 selected countries and EU
313 II, 6. 3. 4 | overall rate of 13 per 100 000 per year, with a countrywide
314 II, 6. 3. 4 | Kingdom) had more than 5 000 cases each, accounting for
315 II, 6. 3. 4 | notification rate (135 per 100 000 per year in 2005) and will
316 II, 6. 3. 4 | stable at around one per 100 000 per year. In 2005, a total
317 II, 6. 3. 4 | incidence of 3.36 per 100 000 per year was seen in Spain,
318 II, 6. 3. 4 | Iceland with 2.38 per 100 000 per year. In 2005, 746 cases
319 II, 6. 3. 5 | five and six cases per 100 000 per year, but this is a
320 II, 6. 3. 5 | one and two cases per 100 000 per year. Good vaccines
321 II, 6. 3. 5 | infections (5.83 per 100 000 per year) were reported
322 II, 6. 3. 5 | countries. Sweden (15.76 per 100 000) followed by Belgium (15.
323 II, 6. 3. 5 | by Belgium (15.45 per 100 000) reported the highest incidence
324 II, 6. 3. 5 | age group (15.3 per 100 000), followed by the under-4
325 II, 6. 3. 5 | age group (14.1 per 100 000), while the incidence rate
326 II, 6. 3. 5 | incidence varied below 2/100 000 per year with stable trends
327 II, 6. 3. 5 | Ireland (with 4.94 per 100 000) and Malta (2.73 per 100
328 II, 6. 3. 5 | and Malta (2.73 per 100 000) reported the highest incidence
329 II, 6. 3. 5 | rate, with 1.48 per 100 000, followed by Sweden (1.31
330 II, 6. 3. 5 | by Sweden (1.31 per 100 000). Hib vaccination is now
331 II, 6. 3. 5 | Netherlands (40.17 per 100 000), with Norway reporting
332 II, 6. 3. 5 | a rate of 19.10 per 100 000. By contrast, the overall
333 II, 6. 3. 5 | the EU was 4.10 per 100 000 per year. Thus pertussis,
334 II, 6. 3. 5 | peaked in 1995 (15 per 100 000 per year) with a second
335 II, 6. 3. 5 | peak in 2000 (11 per 100 000 per year). In Estonia and
336 II, 6. 3. 5 | incidence of 0.87 per 100 000.~ ~Tetanus~ ~Tetanus is
337 II, 6. 3. 5 | always below 0.2 per 100 000 per year in the EU15 states,
338 II, 6. 3. 5 | were below 0.35 per 100 000 per year, except for Slovenia
339 II, 6. 3. 5 | incidence was at 0.45 per 100 000 per year in 2000 (nine cases)
340 II, 6. 3. 5 | for Malta with 0.5 per 100 000 per year in 2002 (two cases).
341 II, 6. 3. 5 | were in Malta (0.25 per 100 000), followed by Italy (0.11
342 II, 6. 3. 5 | followed by Italy (0.11 per 100 000).~ ~
343 II, 6. 3. 5 | years from almost 35 per 100 000 per year before 1997 to
344 II, 6. 3. 5 | to less than 10 per 100 000 per year after 1998 (Figure
345 II, 6. 3. 5 | between five and 42 per 100 000 per year. In the other countries,
346 II, 6. 3. 5 | between one and 10 per 100 000 per year since 2000.~ ~In
347 II, 6. 3. 5 | the EU was 0.28 per 100 000 per year and the highest
348 II, 6. 3. 5 | the highest rates per 100 000 were reported by Ireland (
349 II, 6. 3. 5 | incidence rate below one per 1 000 000 per year during the
350 II, 6. 3. 5 | rate below one per 1 000 000 per year during the past
351 II, 6. 3. 5 | 77.24 and 28.95 per 100 000, respectively). In those
352 II, 6. 3. 5 | countries was 17.65 per 100 000 per year.~ ~Rubella~ ~Rubella
353 II, 6. 3. 5 | incidence was 0.51 per 100 000 per year, with Lithuania (
354 II, 6. 3. 5 | Lithuania (3.44 per 100 000) and the Netherlands (2.
355 II, 6. 3. 5 | Netherlands (2.23 per 100 000) reporting the highest rates.
356 II, 6. 3. 6 | increasing trend from 85 000 cases in 1995, to 180 000–
357 II, 6. 3. 6 | 000 cases in 1995, to 180 000–190 000 more recently, though
358 II, 6. 3. 6 | in 1995, to 180 000–190 000 more recently, though this
359 II, 6. 3. 6 | In 2005, more than 200 000 cases were reported, with
360 II, 6. 3. 6 | Czech Republic (296 per 100 000), followed by the UK (87.
361 II, 6. 3. 6 | by the UK (87.95 per 100 000). Campylobacteriosis is
362 II, 6. 3. 6 | Czech Republic (322 per 100 000), followed by Slovakia (
363 II, 6. 3. 6 | Slovakia (223.67 per 100 000). The highest incidence
364 II, 6. 3. 6 | Norway, with 0.87 per 100 000, reported the highest incidence
365 II, 6. 3. 6 | by the UK (0.79 per 100 000).~ ~Shigellosis~ ~Shigellosis
366 II, 6. 3. 6 | incidence rate was 1.82 per 100 000, with the highest incidence
367 II, 6. 3. 6 | five year-old (3.5 per 100 000), representing 10% of all
368 II, 6. 3. 6 | Lithuania (13.43 per 100 000 total population), followed
369 II, 6. 3. 6 | by Slovakia (9.51 per 100 000) reported the highest national
370 II, 6. 3. 6 | Czech Republic (16.72 per 100 000) followed by Sweden (4.27
371 II, 6. 3. 6 | by Sweden (4.27 per 100 000) reported the highest incidence.
372 II, 6. 3. 6 | Lithuania (14.63 per 100 000) followed by Finland (12.
373 II, 6. 3. 6 | by Finland (12.2 per 100 000) reporting the highest incidence
374 II, 6. 3. 6 | the EU was 2.23 per 100 000 per year, with children
375 II, 6. 3. 6 | incidence (30.4 per 100 000 per year).~ ~Listeriosis~ ~
376 II, 6. 3. 6 | incidence in 2004 (0.28 per 100 000 per year) was similar to
377 II, 6. 3. 6 | 2005. Denmark (0.85 per 100 000), followed by Finland (0.
378 II, 6. 3. 6 | by Finland (0.69 per 100 000) reported the highest incidence
379 II, 6. 3. 6 | from 1999 (just under 4 000 cases (0.87 per 100 000))
380 II, 6. 3. 6 | 000 cases (0.87 per 100 000)) to 2004 (1 743 cases (
381 II, 6. 3. 6 | 743 cases (0.38 per 100 000)). Twenty-six countries
382 II, 6. 3. 6 | incidence of 0.31 per 100 000. Portugal (1.40 per 100
383 II, 6. 3. 6 | Portugal (1.40 per 100 000), followed by Ireland (1.
384 II, 6. 3. 6 | by Ireland (1.29 per 100 000) reported the highest incidence
385 II, 6. 3. 6 | incidence (0.15 per 100 000).~ ~Cholera~ ~Cholera is
386 II, 6. 3. 6 | reported ( 0.01 per 100 000 per year). In 2005, 34 cases
387 II, 6. 3. 6 | is available. Almost 210 000 cases have been reported
388 II, 6. 3. 6 | Slovakia (9.81 per 100 000) and Latvia (6.29 per 100
389 II, 6. 3. 6 | and Latvia (6.29 per 100 000) are the only countries
390 II, 6. 3. 6 | of more than five per 100 000 per year. The highest incidence
391 II, 6. 3. 6 | observed in 1995 (1.68 per 100 000 per year), and has shown
392 II, 6. 3. 6 | Lithuania (6.86 per 100 000), followed by Slovakia (
393 II, 6. 3. 6 | by Slovakia (4.85 per 100 000) reporting the highest incidence.
394 II, 6. 3. 6 | Estonia (24.28 per 100 000), followed by Iceland (14.
395 II, 6. 3. 6 | by Iceland (14.65 per 100 000) reported the highest incidence
396 II, 6. 3. 6 | scanty. In 2005, almost 8 000 cases were reported by 16
397 II, 6. 3. 6 | with Ireland (13.75 per 100 000) and the UK (9.26 per 100
398 II, 6. 3. 6 | and the UK (9.26 per 100 000) reporting the highest incidence
399 II, 6. 3. 6 | Lithuania (0.44 per 100 000), followed by Slovenia (
400 II, 6. 3. 6 | by Slovenia (0.30 per 100 000), reported the highest incidence
401 II, 6. 3. 6 | countries. Latvia (2.12 per 100 000), followed by Lithuania (
402 II, 6. 3. 6 | Lithuania (0.35 per 100 000) reported the highest incidence
403 II, 6. 3. 7 | countries. Sweden (2.73 per 100 000), followed by Hungary (0.
404 II, 6. 3. 7 | by Hungary (0.86 per 100 000) reported the highest incidence
405 II, 6. 3. 7 | 2 and 0.5 cases per 100 000. In 2005, 958 cases were
406 II, 6. 3. 7 | incidence rates (0.49 per 100 000 and 0.48 per 100 000, respectively).
407 II, 6. 3. 7 | 100 000 and 0.48 per 100 000, respectively). This is
408 II, 6. 3. 7 | 1 to 0.22 cases per 100 000. The lowest number of cases
409 II, 6. 3. 7 | with Estonia (0.82 per 100 000) followed by France (0.77
410 II, 6. 3. 7 | by France (0.77 per 100 000) reporting the highest incidence.~ ~
411 II, 6. 3. 7 | from 1.45 to 2.27 per 100 000 per year, with a steady
412 II, 7. 1 | each year and about 250,000 citizens of the European
413 II, 7. 3. 1 | population of Italy:~ ~- 252 000 Fatal Injuries~- 7 000 000
414 II, 7. 3. 1 | 252 000 Fatal Injuries~- 7 000 000 Hospital Admissions~-
415 II, 7. 3. 1 | 000 Fatal Injuries~- 7 000 000 Hospital Admissions~- 34
416 II, 7. 3. 1 | Hospital Admissions~- 34 200 000 Hospital Outpatients~- 18
417 II, 7. 3. 1 | Hospital Outpatients~- 18 300 000 Other medical Treatment~ ~·
418 II, 7. 3. 2 | estimated that almost 100 000 lives could be saved each
419 II, 7. 3. 2 | 72 injury deaths per 100 000 males) than it is for females (
420 II, 7. 3. 2 | for females (35 per 100 000 females). As a result, 66%
421 II, 7. 3. 2 | 3. Injury deaths per 100 000 by sex and age group, EU27~ ~
422 II, 7. 3. 3 | 7 million, more than 19,000 people each day and nearly
423 II, 7. 3. 3 | due to injuries per 100 000 inhabitants in the EU27
424 II, 7. 3. 4 | a daily basis. Almost 50 000 road fatalities (definition
425 II, 7. 3. 4 | EU27 range from 4 per 100 000 inhabitants in Malta to
426 II, 7. 3. 4 | and the WHO, more than 6 000 work place fatalities are
427 II, 7. 3. 4 | They range from 0.3 per 100 000 inhabitants in the United
428 II, 7. 3. 4 | in the EU27 is 22 per 100,000 residents and is more than
429 II, 7. 3. 4 | every year more than 100 000 EU citizens die from home
430 II, 7. 3. 5 | of all cases, almost 61 000 people a year – see Figure
431 II, 7. 3. 5 | vary from about 2 per 100 000 people in Cyprus to 35 per
432 II, 7. 3. 5 | in Cyprus to 35 per 100 000 in Lithuania (Figure 7.15.
433 II, 7. 4. 1 | Every year more than 20 000 people in this age group
434 II, 7. 4. 2 | Every year approximately 105 000 people aged 65 or older
435 II, 7. 4. 3 | of injury. Each year, 45 000 people are killed on EU
436 II, 7. 4. 4 | EU-region counts some 700 000 sport clubs.~ ~However,
437 II, 7. 7 | Standardised Death Rate (per 100 000 inhabitants), Suicide and
438 II, 7. 7 | Standardised Death Rate (per 100 000 inhabitants), Homicide,
439 II, 8. 2. 1 | with sample sizes of N=1,000, to population based census
440 II, 9 | Region before age 65, per 100.000 population.~ ~ ~ ~Source:
441 II, 9. 1 | Of these, an estimated 25 000 are stillborn and an additional
442 II, 9. 1 | stillborn and an additional 25 000 die within their first year (
443 II, 9. 1 | survivors, an additional 40 000 (approximately 8 per 1 000
444 II, 9. 1 | 000 (approximately 8 per 1 000 survivors) experience severe
445 II, 9. 1 | frequently - only 5 to 15 per 100 000 live births – but are associated
446 II, 9. 1. 1 | ranged from 6.4 to 22.1 per 1 000 total births in the current
447 II, 9. 1. 1 | ranged from 1.6 to 9.5 per 1 000 births. Neonatal mortality
448 II, 9. 1. 1 | rates are about 2 per 1 000 births in Sweden, Luxembourg,
449 II, 9. 1. 1 | Finland, but over 5 per 1 000 in Bulgaria, Latvia and
450 II, 9. 1. 1 | mortality in 2004 was 2.7 per 1 000 births. This median rate
451 II, 9. 1. 1 | rate was much higher (4.4/1 000) among countries that joined
452 II, 9. 1. 1 | three times greater (8.5/1 000) among countries that acceded
453 II, 9. 1. 1 | foetal mortality (3.9 per 1 000 births) between the original
454 II, 9. 1. 1 | was higher at 6.9 per 1 000 births.~ ~F ~ ~Infant mortality
455 II, 9. 1. 1 | occurring in 1.5 to 2.5 per 1 000 live births. Cerebral Palsy
456 II, 9. 1. 1 | countries, is 2.0 per 1 000 live births. As shown in
457 II, 9. 1. 1 | Cerebral palsy rates per 1 000 live births in selected
458 II, 9. 1. 1 | is, on average, 94 per 1 000 live births during the period
459 II, 9. 1. 1 | per country from 26 per 1 000 live births (Lithuania)
460 II, 9. 1. 1 | Lithuania) up to 164 per 1 000 live births (Ireland). This
461 II, 9. 1. 2 | anomalies of 23.8 per 1 000 births for 2000-2004 (Table
462 II, 9. 1. 2 | prevalence is 19.9 per 1 000 births.~ ~Table 9.1.2.1.
463 II, 9. 1. 2 | 1.2.1. Prevalence per 1 000 births of EUROCAT congenital
464 II, 9. 1. 2 | chromosomal anomalies is 3.4 per 1 000 births. In the data shown
465 II, 9. 1. 2 | common subgroup, at 6.4 per 1 000 births, followed by limb
466 II, 9. 1. 2 | limb defects (3.6 per 1 000), urinary system (2.8 per
467 II, 9. 1. 2 | urinary system (2.8 per 1 000) and nervous system defects (
468 II, 9. 1. 2 | system defects (2.0 per 1 000). EUROCAT updates each year
469 II, 9. 1. 2 | prevalence above 0.1 per 1 000 births are shown in Table
470 II, 9. 1. 2 | live birth prevalence per 1 000 births of All Anomalies
471 II, 9. 1. 2 | congenital anomaly is 0.43 per 1 000 births, and deaths in the
472 II, 9. 1. 2 | the first week 0.55 per 1 000 births, giving a total perinatal
473 II, 9. 1. 2 | congenital anomaly of 0.99 per 1 000 births (Table 9.1.2.2).
474 II, 9. 1. 2 | recorded in Italy (0.2 per 1 000) but there is a known problem
475 II, 9. 1. 2 | recorded in Ireland (2.4 per 1 000) and Malta (2.3 per 1 000).
476 II, 9. 1. 2 | 000) and Malta (2.3 per 1 000). These are both countries
477 II, 9. 1. 2 | Perinatal Mortality per 1 000 births, by country, 2000-
478 II, 9. 1. 2 | to 11.4 (France) per 1 000 births. Differing prenatal
479 II, 9. 1. 2 | France (5.6 and 5.8 per 1 000 births respectively). Comparison
480 II, 9. 1. 2 | heart disease is 6.1 per 1 000 births (Table 9.1.2.1),
481 II, 9. 1. 2 | prevalence of 8-10 per 1 000. The reported prevalence
482 II, 9. 1. 2 | across Europe, to 2.2 per 1 000 births. Geographical variation
483 II, 9. 1. 2 | and TOPFA) of 3.4 per 1 000.~ ~Figure 9.1.2.2. Trends
484 II, 9. 1. 2 | live birth prevalence per 1 000 births of Down Syndrome,
485 II, 9. 1. 2 | Figure 9.1.2.2) to 1.0 per 1 000 births as the increase in
486 II, 9. 1. 2 | ranging from 0.4 per 1 000 to 2.0 per 1 000 (the high
487 II, 9. 1. 2 | 4 per 1 000 to 2.0 per 1 000 (the high rates being in
488 II, 9. 1. 2 | live birth prevalence per 1 000 births of Neural Tube Defects
489 II, 9. 1. 2 | live birth prevalence per 1 000 births of Neural Tube Defects,
490 II, 9. 1. 2 | prevalence rates, from 0.1 per 1 000 in France and Spain to 1.
491 II, 9. 1. 2 | France and Spain to 1.0 per 1 000 in Poland (Table 9.1.2.4).~ ~
492 II, 9. 1. 2 | cleft lip occur in 1.3 per 1 000 births in Europe (Table
493 II, 9. 1. 2 | between 1.3 and 1.6 per 1 000 for 2000-2004 (EUROCAT,
494 II, 9. 1. 2 | while rates of 0.6 per 1 000 or below were recorded in
495 II, 9. 1. 2 | prevalence of 0.2 per 1 000 births in 2000-2004 (Table
496 II, 9. 1. 2 | of a minimum of 1.3 per 1 000 births (Table 9.1.2.1).
497 II, 9. 1. 2 | prevalence rates up to 2.5 per 1 000 in the period 2000-2004,
498 II, 9. 1. 2 | prevalence – Sicily at 3.0 per 1 000, and Malta at 4.2 per 1
499 II, 9. 1. 2 | and Malta at 4.2 per 1 000. It is difficult to produce
500 II, 9. 1. 2 | prevalence less than 5 per 10 000 in the EU), depending on
|
|
| |
